drugset / Trial / NCT00222469
Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer
Phase 2
Completed
50 enrolled
University of Oklahoma
Genentech, Inc. · collabM.D. Anderson Cancer Center · collabSanofi · collab
Non-randomizedSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to find out if giving patients bevacizumab along with the chemotherapy drugs oxaliplatin and gemcitabine will improve overall survival. In addition, the study will find out what side effects patients may have by taking bevacizumab, oxaliplatin, and gemcitabine together.
Timeline
- Start
- 2005-08
- Primary completion
- 2007-05
- Completion
- 2007-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | — |